title: Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up.
abstract: Herpes simplex virus (HSV) infections are very common in the general population and among immunocompromised patients. Acyclovir (ACV) is an effective treatment which is widely used. We deemed it essential to conduct a wide and coordinated survey of the emergence of ACV-resistant HSV strains. We have formed a network of 15 virology laboratories which have isolated and identified, between May 1999 and April 2002, HSV type 1 (HSV-1) and HSV-2 strains among hospitalized subjects. The sensitivity of each isolate to ACV was evaluated by a colorimetric test (C. Danve, F. Morfin, D. Thouvenot, and M. Aymard, J. Virol. Methods 105:207-217, 2002). During this study, 3900 isolated strains among 3357 patients were collected; 55% of the patients were immunocompetent. Only six immunocompetent patients excreted ACV-resistant HSV strains (0.32%), including one female patient not treated with ACV who was infected primary by an ACV-resistant strain. Among the 54 immunocompromised patients from whom ACV-resistant HSV strains were isolated (3.5%), the bone marrow transplantation patients showed the highest prevalence of resistance (10.9%), whereas among patients infected by human immunodeficiency virus, the prevalence was 4.2%. In 38% of the cases, the patients who excreted the ACV-resistant strains were treated with foscarnet (PFA), and 61% of them developed resistance to PFA. The collection of a large number of isolates enabled an evaluation of the prevalence of resistance of HSV strains to antiviral drugs to be made. This prevalence has remained stable over the last 10 years, as much among immunocompetent patients as among immunocompromised patients.
authors.affiliation: CHU Lyon, 69373 Lyon Cedex 08, Paris, France. christelle.szatanek@free.fr
authors.forename: C
authors.initials: C
authors.lastname: Danve-Szatanek
authors.forename: M
authors.initials: M
authors.lastname: Aymard
authors.forename: D
authors.initials: D
authors.lastname: Thouvenot
authors.forename: F
authors.initials: F
authors.lastname: Morfin
authors.forename: G
authors.initials: G
authors.lastname: Agius
authors.forename: I
authors.initials: I
authors.lastname: Bertin
authors.forename: S
authors.initials: S
authors.lastname: Billaudel
authors.forename: B
authors.initials: B
authors.lastname: Chanzy
authors.forename: M
authors.initials: M
authors.lastname: Coste-Burel
authors.forename: L
authors.initials: L
authors.lastname: Finkielsztejn
authors.forename: H
authors.initials: H
authors.lastname: Fleury
authors.forename: T
authors.initials: T
authors.lastname: Hadou
authors.forename: C
authors.initials: C
authors.lastname: Henquell
authors.forename: H
authors.initials: H
authors.lastname: Lafeuille
authors.forename: M E
authors.initials: ME
authors.lastname: Lafon
authors.forename: A
authors.initials: A
authors.lastname: Le Faou
authors.forename: M C
authors.initials: MC
authors.lastname: Legrand
authors.forename: L
authors.initials: L
authors.lastname: Maille
authors.forename: C
authors.initials: C
authors.lastname: Mengelle
authors.forename: P
authors.initials: P
authors.lastname: Morand
authors.forename: F
authors.initials: F
authors.lastname: Morinet
authors.forename: E
authors.initials: E
authors.lastname: Nicand
authors.forename: S
authors.initials: S
authors.lastname: Omar
authors.forename: B
authors.initials: B
authors.lastname: Picard
authors.forename: B
authors.initials: B
authors.lastname: Pozzetto
authors.forename: J
authors.initials: J
authors.lastname: Puel
authors.forename: D
authors.initials: D
authors.lastname: Raoult
authors.forename: C
authors.initials: C
authors.lastname: Scieux
authors.forename: M
authors.initials: M
authors.lastname: Segondy
authors.forename: J M
authors.initials: JM
authors.lastname: Seigneurin
authors.forename: R
authors.initials: R
authors.lastname: Teyssou
authors.forename: C
authors.initials: C
authors.lastname: Zandotti
mesh_terms: D000212:Acyclovir / Q000494:pharmacology*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D016026:Bone Marrow Transplantation; D002522:Chlorocebus aethiops; D024882:Drug Resistance, Viral; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016377:Organ Transplantation; D018139:Simplexvirus / Q000187:drug effects*; D014709:Vero Cells
chemical_list: D000998:Antiviral Agents; D000212:Acyclovir